Dunlop Boadie W, Papp Laszlo, Garlow Steven J, Weiss Paul S, Knight Bettina T, Ninan Philip T
Department of Psychiatry & Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30329, USA.
Hum Psychopharmacol. 2007 Jun;22(4):241-4. doi: 10.1002/hup.846.
Tiagabine, a selective gamma-aminobutyric acid (GABA) reuptake inhibitor was evaluated for the treatment of patients with social anxiety disorder (SAD). Adults with SAD received open-label tiagabine 4-16 mg per day for 12 weeks. Intent-to-treat data are available for 54 patients with improvement demonstrated in Liebowitz Social Anxiety Scale, Clinician Global Impression-Severity (CGI-S) and -Improvement (CGI-I), Social Phobia Inventory, and Sheehan Disability Scale scores. In all, 40.7% (22/54) of the intent to treat sample and 63.0% (17/27) of the completer sample were considered CGI responders (CGI-I score of one or two). Tiagabine was generally well tolerated. Results of this pilot study suggest that tiagabine may be an option for the treatment of patients with SAD. Larger, controlled studies are required to fully elucidate the potential of tiagabine for the treatment of SAD.
替加宾，一种选择性γ-氨基丁酸（GABA）再摄取抑制剂，被评估用于治疗社交焦虑障碍（SAD）患者。患有SAD的成年人接受了为期12周的开放标签的替加宾治疗，剂量为每日4 - 16毫克。意向性治疗数据来自54名患者，在利伯维茨社交焦虑量表、临床医生整体印象-严重程度（CGI-S）和-改善程度（CGI-I）、社交恐惧症量表以及希恩残疾量表评分中均显示出改善。总体而言，意向性治疗样本中有40.7%（22/54）以及完成治疗样本中有63.0%（17/27）被视为CGI反应者（CGI-I评分为1或2）。替加宾总体耐受性良好。这项初步研究的结果表明，替加宾可能是治疗SAD患者的一种选择。需要开展更大规模的对照研究，以充分阐明替加宾治疗SAD的潜力。
